Do you know your type 1 diabetes (T1D) members?

T1D accounts for close to 6% of your diabetes patients, and because it is an autoimmune disease, these patients are different from the type 2 population. A greater understanding of the autoimmune nature of T1D may lead to a novel approach to therapy for these patients.

Understand the impact of T1D on your member population

The autoimmune genesis of T1D

T1D is an autoimmune disease and can be detected at early stages. Learn more about the autoimmune origin, which may shed light on strategies to screen populations and potential interventions.


Identifying early signs may mitigate risk

T1D develops in stages. And early, subclinical stages can be detected.


Screening for T1D with a blood test may help early detection

Proactive screening has been shown to reduce dangerous outcomes like diabetic ketoacidosis (DKA).


Current treatment options address the symptoms of T1D

Even with advanced tools such as continuous glucose monitoring, many T1D patients are poorly controlled. That is because current therapies treat the effects of T1D, not the cause.